Mirati Therapeutics (MRTX)
B.Riley FBR analyst Harshita Polishetty reiterated a Hold rating on Mirati Therapeutics yesterday and set a price target of $83. The company’s shares closed last Monday at $79.71.
“Amgen’s follow-up on its competing KRAS G12C inhibitor at WCLC 2019 over the Sept. 6-7 weekend included an overall response rate (ORR) of 54% (7/13) in patients with non-small cell lung cancer (NSCLC) at the 960 mg dose (recommended Phase II dose), down from 100% (3/3), which was previously reported at ASCO in June. Although it is common for response rates to decline over time with longer follow-up and increase in patient numbers, what concerned us was the low durability reported for the patient subset, which we expand on below. In light of these updates, we are lowering our PT from $92 to $83. We reiterate our Neutral rating.”
According to TipRanks.com, Polishetty is a 5-star analyst with an average return of 33.1% and a 66.7% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.
Currently, the analyst consensus on Mirati Therapeutics is a Moderate Buy with an average price target of $101.78, implying a 25.5% upside from current levels. In a report issued on September 9, Deutsche Bank also maintained a Hold rating on the stock with a $68 price target.
Needham analyst Michael Matson maintained a Buy rating on Atricure today and set a price target of $39. The company’s shares closed last Monday at $23.88, close to its 52-week low of $22.57.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 6.7% and a 63.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Boston Scientific Corp, and Cardiovascular Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atricure with a $36.80 average price target, implying a 53.9% upside from current levels. In a report issued on September 6, J.P. Morgan also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.